Company to Deliver Seven Data Presentations at World’s Largest International Ophthalmology Gathering

RESEARCH TRIANGLE PARK, NC May 5, 2017 – Envisia Therapeutics today announced that the Company will present new data for its next generation product candidate, ENV515 for glaucoma, as well as new data from its back of the eye programs, at the Association for Research in Vision and Ophthalmology’s (ARVO) Annual Meeting being held May 7-11, 2017 in Baltimore, MD.  Read more here.

Company to Deliver Key Data Presentations at the Pre-Eminent Meeting for Ophthalmologists Specializing in Anterior Segment

RESEARCH TRIANGLE PARK, NC May 3, 2017 – Envisia Therapeutics today announced that the Company will present new data for its next generation product candidates, ENV515 for glaucoma and ENV1105 for diabetic macular edema, at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium and Congress being held May 5-9, 2017 in Los Angeles, CA. ASCRS is the largest US meeting dedicated exclusively to the needs of the anterior segment specialist. Read more here.

Company to Present at the Largest Gathering of US Glaucoma Specialists

RESEARCH TRIANGLE PARK, NC March 2, 2017 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today announced that it will present a podium presentation and two posters at the American Glaucoma Society (AGS) Annual Meeting being held March 2-6, 2017 in San Diego, CA. Read more here.

Results Provide Encouraging Outlook for Extended Treatment of Glaucoma Patients

RESEARCH TRIANGLE PARK, NC – FEBRUARY 3, 2017 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today released an interim analysis of the second cohort of its ENV515 (travoprost XR) phase 2 trial in patients with glaucoma showing a clinically meaningful reduction in intraocular pressure (IOP) for the entire 11-month evaluation period following a single administration. ENV515 also demonstrated an IOP lowering effect comparable to prestudy topical prostaglandin analogs (XALATAN® and LUMIGAN®) and in-study topical timolol maleate 0.5% ophthalmic solution (daily eye drops). Glaucoma is the leading cause of preventable vision loss and blindness due largely in part to poor patient compliance with once-daily eye drops. Read more here.

RESEARCH TRIANGLE PARK, NC January 4, 2017 – Envisia Therapeutics today announced that Company President, Dr. Benjamin Yerxa, has been invited to present at the 35th Annual J.P. Morgan Healthcare Conference taking place January 9 -13th, 2017 in San Francisco, CA. The J.P. Morgan Healthcare Conference continues to be one of the life science industry’s largest conferences of the year, bringing thousands of investors and executives from around the world to exchange the latest innovations in the industry. Read more here.

Results Provide Encouraging Outlook for Extended Treatment of Glaucoma Patients

 RESEARCH TRIANGLE PARK, NC – OCTOBER 17, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today released an interim analysis of its ENV515 (travoprost XR) phase 2 trial in glaucoma patients showing clinically meaningful reduction in intraocular pressure (IOP) for the entire nine-month evaluation period following a single administration. ENV515 also demonstrated an IOP lowering effect comparable to prestudy topical prostaglandin analogs (XALATAN® and LUMIGAN®) and in-study topical timolol maleate 0.5% ophthalmic solution (daily eye drops). Glaucoma is the leading cause of preventable vision loss and blindness due largely in part to poor patient compliance with once-daily eye drops. Read more here.

Company to Highlight Novel Approach to Developing Extended-­‐Release Ocular Therapies

 RESEARCH TRIANGLE PARK, NC October 10, 2016 – Envisia Therapeutics today announced that it has been selected to present during the Anterior Segment Company Showcase at the 2016 Ophthalmology Innovation Summit (OIS) being held at 8:30am CDT on October 13, 2016 at the Planet Hollywood Hotel in Chicago, Illinois. Commonly referred to as OIS@AAO, the summit is held each year in conjunction with the American Academy of Ophthalmology (AAO) Annual Meeting to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Read more here.

RESEARCH TRIANGLE PARK, NCSeptember 1, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, announced today that Dr. Benjamin Yerxa will participate in a panel titled “Emerging Innovators – An Introduction to Private Biotech Companies” at Citi’s 11th Annual Biotech Conference in Boston, MA on Thursday, September 8, 2016.  Read more here.

RESEARCH TRIANGLE PARK, NCAugust 10, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, announced today that Dr. Benjamin Yerxa will present at the Wedbush PacGrow Healthcare Conference in New York, NY on Wednesday, August 17, 2016.  Read more…

RESEARCH TRIANGLE PARK, NC – July 27, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, announced today that it will present at the Ophthalmic Drug Development Summit taking place July 26 – 28, 2016 in Washington, DC. Read More


1 2 3 4
Copyright 2013 Envisia Therapeutics